UK Committee Wants Compulsory Licensing To Secure Cheap COVID-19 Products
ABPI Says Suggestion Is ‘Disappointing’
Some way needs to be found to guarantee the supply of coronavirus products as more of them begin to become available, but the pharmaceutical industry says compulsory licensing is not the answer.
You may also be interested in...
A parliamentary committee has come up with some ideas for strengthening the UK’s response to future demand surges due to the spread of COVID-19.
State-imposed mechanisms such as compulsory licensing will discourage rather than encourage investment in R&D, says Europe’s research-based industry. It has also dismissed suggestions that Europe is too dependent on API supplies from third countries.
Coronavirus Notebook: EMA Data Hack Aimed At 'Undermining Trust' In Vaccines, Russia Plans EU Sputnik V Filing Next Month
France has reported on side-effect reports concerning the Pfizer/BioNTech vaccine, and the World Health Organization has warned that plans to provide global equitable access to coronavirus vaccines are at risk.